Skip to content

Aquacel Hypersensitivity Dressing in TJAs

Prospective Evaluation of Type IV Hypersensitivity Reactions After Aquacel Dressing Application in Partial and Total Joint Arthroplasty Patients

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06011629
Enrollment
457
Registered
2023-08-25
Start date
2023-06-18
Completion date
2025-06-03
Last updated
2026-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adverse Skin Reaction, Contact Allergic Dermatitis

Brief summary

The aim of this multi-surgeon, single institution study is to prospectively evaluate the incidence of allergic contact dermatitis (ACD) following application of AQUACEL Ag, a silver-containing hydrofiber dressing, in total hip and knee arthroplasty patients. Arthroplasty-naïve patients will be compared to prior total joint arthroplasty patients who received a Aquacel dressing postoperatively.

Detailed description

Level I: Prospective Cohort Study Patients will be recruited into the study after completing a standard questionnaire for pre-operative enrollment. After meeting inclusion criteria and passing the screening process, the patient will be enrolled into the study. Variables of interest related to sociodemographic status, operative details and postoperative outcomes. Sample Size: A power analysis to determine how many patients need to be enrolled was performed with a rate of ACD in the AQUACEL Ag naïve group and the AQAUCEL Ag-exposed group of 1% and 2%, respectively. A one-tailed z-test of proportions between the two groups with 80% power, a 5% level of significance, and 1:1 allocation ratio, requires a sample size of 314 (157 per group). To account for 20% attrition rate amongst both cohorts, we plan to enroll 400 patients (200 each group). Demographic/Patient Specific Data Collected: Age, Sex, Body Mass Index (BMI), Allergy History, Past Surgical History, Prior exposure to surgical dressing (Either occupational (i.e. healthcare worker) or as a patient), Number of prior arthroplasty surgeries with AQUACEL Ag dressing (i.e. 0, 1, 2, 3), Past adverse reaction to AQUACEL Ag dressing, Any Adverse Skin Reactions with any past adhesive exposure Operative details: Surgical date, Operation/Laterality (THA/TKA/UKA, Left/Right), Length of incision, Patient reported skin check at 1 week (via picture from patient if wound issue/skin reaction present), Size of Rash if present, Provider skin Check at 1st post-operative appointment (2-4 weeks post-op), Any Wound Complications Primary Outcome Measure: The primary outcome is the rate of contact allergic dermatitis or adverse skin reaction at 1 week post op and 1st post operative visit (2-3 weeks after surgery). We will also quantify time from surgery to reaction onset (Days). We will measure the size of the rash at post-operative follow up as well as classify the rash according to the classification system used in prior studies examining ACD. Secondary Outcome Measures 1. Wound complications 2. Any workup for PJI (Serologic labs (ESR/CRP), arthrocentesis) 3. Any administration of post-operative antibiotics outside of normal protocol 4. Return to Operating Room for debridement, manipulation, other surgical interventions 5. Surgical Site Infection (SSI) 6. Confirmed Periprosthetic Joint Infection (PJI) 7. Stiffness requiring Manipulation Under Anesthesia (MUA)

Interventions

DEVICEAquacel dressing

Patients will be recruited into the study after completing a standard questionnaire for pre-operative enrollment. After meeting inclusion criteria and passing the screening process, the patient will be enrolled into the study. Arthroplasty-naïve patients will be compared to prior total joint arthroplasty patients who received a Aquacel dressing postoperatively.

Sponsors

Rush University Medical Center
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Patients older than 18 years that underwent primary total hip arthroplasty (THA) 2. Patients older than 18 years that underwent primary total or unicompartmental knee arthroplasty (TKA/UKA)

Exclusion criteria

1. Revision surgery 2. Prior history of allergic contact dermatitis 3. Prior history of non-TJA or UKA surgery with AQUACEL Ag dressing post-op 4. Occupational exposure to surgical dressings 5. Documented history of silver allergy

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants With Contact Allergic Dermatitis or Adverse Skin Reaction at 2 Weeks Post Surgery14 days post surgeryUsing a classification of skin reactions from mild, moderate to severe

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORVasili Karas, MD

Rush University Medical Center

Baseline characteristics

Characteristic
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
71 Participants
Age, Categorical
Between 18 and 65 years
275 Participants
Age, Continuous63.6 year
STANDARD_DEVIATION 7.8
Race and Ethnicity Not Collected0 Participants
Region of Enrollment
United States
457 participants
Sex: Female, Male
Female
231 Participants
Sex: Female, Male
Male
142 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 1770 / 280
other
Total, other adverse events
0 / 1770 / 280
serious
Total, serious adverse events
0 / 1770 / 280

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 5, 2026